Can blood-based markers predict RECIST progression in non-small cell lung cancer treated with immunotherapy?
Journal of Cancer Research and Clinical Oncology · 2024
DOI: 10.1007/s00432-024-05814-2 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Cancer Research and Clinical Oncology, 2024. Verfasst von Melda Yeghaian und 8 weiteren Autor:innen. Beteiligte Einrichtung: GROW Research Institute for Oncology and Reproduction, Maastricht University, Maastricht, The Netherlands. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Biomarkers, Tumor, Immune Checkpoint Inhibitors. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Purpose
In this study, we aimed to evaluate the potential of routine blood markers, serum tumour markers and their combination in predicting RECIST-defined progression in patients with stage IV non-small cell lung cancer (NSCLC) undergoing treatment with immune checkpoint inhibitors.
Methods
We employed time-varying statistical models and machine learning classifiers in a Monte Carlo cross-validation approach to investigate the association between RECIST-defined progression and blood markers, serum tumour markers and their combination, in a retrospective cohort of 164 patients with NSCLC.
Results
The performance of the routine blood markers in the prediction of progression free survival was moderate. Serum tumour markers and their combination with routine blood markers generally improved performance compared to routine blood markers alone. Elevated levels of C-reactive protein (CRP) and alkaline phosphatase (ALP) ranked as the top predictive routine blood markers, and CYFRA 21.1 was consistently among the most predictive serum tumour markers. Using these classifiers to predict overall survival yielded moderate to high performance, even when cases of death-defined progression were excluded. Performance varied across the treatment journey.
Conclusion
Routine blood tests, especially when combined with serum tumour markers, show moderate predictive value of RECIST-defined progression in NSCLC patients receiving immune checkpoint inhibitors. The relationship between overall survival and RECIST-defined progression may be influenced by confounding factors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- GROW Research Institute for Oncology and Reproduction, Maastricht University, Maastricht, The Netherlands.
- Radiology Department, Netherlands Cancer Institute, Amsterdam, The Netherlands.
- Pulmonology Department, Leiden University Medical Center, Leiden, The Netherlands.
- Faculty of Health Sciences, University of Southern Denmark, Odense, Denmark.
- Department of Laboratory Medicine, Netherlands Cancer Institute, Amsterdam, The Netherlands.
- GROW Research Institute for Oncology and Reproduction, Maastricht University, Maastricht, The Netherlands. stefano.trebeschi@maastrichtuniversity.nl.
Zitieren
APA
Yeghaian, M., Tareco Bucho, T. M., de Bruin, M., Schmitz, A., Bodalal, Z., Smit, E. F., Beets-Tan, R. G. H., van den Broek, D., & Trebeschi, S. (2024). Can blood-based markers predict RECIST progression in non-small cell lung cancer treated with immunotherapy?. Journal of Cancer Research and Clinical Oncology. https://doi.org/10.1007/s00432-024-05814-2
Vancouver
Yeghaian M, Tareco Bucho TM, de Bruin M, Schmitz A, Bodalal Z, Smit EF, et al. Can blood-based markers predict RECIST progression in non-small cell lung cancer treated with immunotherapy?. Journal of Cancer Research and Clinical Oncology. 2024. doi:10.1007/s00432-024-05814-2
BibTeX
@article{Yeghaian2024,
author = {Yeghaian, Melda and Tareco Bucho, Teresa M and de Bruin, Melissa and Schmitz, Alexander and Bodalal, Zuhir and Smit, Egbert F and Beets-Tan, Regina G H and van den Broek, Daan and Trebeschi, Stefano},
title = {Can blood-based markers predict RECIST progression in non-small cell lung cancer treated with immunotherapy?},
journal = {Journal of Cancer Research and Clinical Oncology},
year = {2024},
doi = {10.1007/s00432-024-05814-2}
}
EUVIMED